Contact Us
Portal Login
  1. Home
  2. Fibrinet® PRF Wound Matrix
From The Patient. For The Patient.
Fibrinet® PRF Wound Matrix represents an easy and efficient method to harness and concentrate a patient’s own platelets and associated growth factors into a durable Platelet-Rich Fibrin Matrix (PRFM).

Fibrinet® PRF Wound Matrix is designed to support the body’s natural healing processes by delivering a structured, autologous fibrin matrix directly to the wound site. The result is a simple, point-of-care solution that integrates seamlessly into advanced wound management protocols while leveraging the patient’s own biologic potential.

92% OF WOUNDS ACHIEVED ≥ 50% REDUCTION IN WOUND SIZE 1
57% COMPLETE CLOSURE AT 12 WEEKS 1
MEAN TIME TO HEAL: 6.75 WEEKS 1

Autologous PRF Matrix For Wound Management

Key Features of the Fibrinet® PRF Wound Matrix System

  • The system provides intact, concentrated platelets in a platelet-rich fibrin membrane graft without thrombin 2,5
  • Sustained availability of platelets and associated growth factors out to seven days; ability to proliferate cells in vitro 2-4
  • Easy-to-use, closed system with the highest platelet capture efficiency and reproducibility 5
  • Under the supervision of a healthcare professional, the PRP gel produced may be topically applied for the management of cutaneous wounds, including: Diabetic ulcers, Venous leg ulcers, Mechanically or surgically debrided wounds.

How It Works

Coverage

  • Single Kit: Covers up to 6 cm2
  • Double Kit: Covers up to 12 cm2

Structual Strength

Mechanical characterization of bifacial PRFM demonstrates improved structural stiffness compared to conventional fibrin gels, creating a durable fibrin scaffold designed to support the wound environment. 2

Biological Activity

Preclinical would models have demonstrated that PRFM can support endothelial cell proliferation and the expression of associated tissue repair markers.3 Clinical observational studies have reported wound reduction and closure in chronic lower extremity ulcers treated with PRFM.3 1,7

Simple, Safe Point-of-care Preparation

Draw

Spin

Transfer

Spin

Apply

Core Elements of Tissue Repair

Scaffold

Fibrinet® prepares an autologous platelet-rich fibrin membrane from a small sample of the patient’s blood at the point of care without the use of exogenous activators such as bovine thrombin.

The resulting PRFM demonstrates enhanced mechanical properties compared with conventional fibrin clots, with stiffness up to 600× greater and mechanical characteristics comparable to arterial tissue.2

Signals

Autologous platelets contain numerous growth factors that support the wound healing cascade. Preclinical models evaluating PRFM have demonstrated sustained concentrations of key growth factors for up to seven days, including:
  • VEGF – associated with angiogenesis and the formation of new blood vessel formation 2,8
  • PDGF-A/B – involved in cellular recruitment and matrix formation during tissue repair 2
  • TGF-B1 – involved in regulation of fibroblast activity during tissue repair 2

Cells

Scanning electron microscopy has demonstrated intact platelets within the fibrin matrix. An additional preclinical (ex-vivo/in-vitro) study demonstrated greater than 50% platelet viability for up to seven days.2
Scanning Electron Micrograph (SEM) image shows a robust, fibrin scaffold with clusters of platelets in the PRFM (HD)
Image 1: 65 year old male with history of ulcer submetatarsal right #1 for 6 months a) Screening Visit [SV1] b) Application Visit, 2 weeks post-screening [TV1], c) Treatment Visit #3 [TV3], d) Ulcer closed on Treatment Visit #5 [TV5] 9

ORDERING INFORMATION

  • Part NumberDescription
  • PRF-01 Fibrinet PRF Wound Matrix, Single Kit
  • PRF-02 Fibrinet PRF Wound Matrix, Double Kit

REFERENCES

1. Fridman R, Wielgomas J. A Prospective Study to Evaluate Efficacy and Safety of Autologous Platelet-Rich Fibrin Matrix for the Treatment of Chronic Diabetic Foot Ulcers. Clin Res Foot Ankle. 2024;12:590. doi:10.4172/2329-910X.1000590.

2. Lucarelli E, et al. A recently developed bifacial platelet-rich fibrin matrix. Eur Cells Materials 2010; 20:13-23.

3. Roy S, Sen CK, et al. Platelet-rich fibrin matrix improves wound angiogenesis via inducing endothelial cell proliferation. Wound Rep Regen. 2011;19(6):753-766.

4. Visser LC, Arnoczky SP, Caballero O, et al. Platelet-rich fibrin constructs elute higher concentrations of TGF-ß1 and increase tendon cell proliferation over time when compared to blood clots of similar volume: A comparative in vitro analysis. Vet Surg. 2010c; 39(7):811-817.

5. Castillo TN, Pouliot MA, Kim HJ, Dragoo JL. Comparison of growth factor and platelet concentration from commercial PRP separa- tion systems. Am J Sports Med. ePub Nov 4, 2010.

6. Roy S., Driggs J., Elgharably H., et al. Platelet-rich fibrin matrix improves wound angiogenesis via inducing endothelial cell proliferation. Wound Repair Regen. 2011;19:753-766.

7. O’Connell SM, Impeduglia T, Hessler K, Wang X-J, Carroll RJ, Dardik H.Autologous platelet-rich fibrin matrix as cell therapy in the healing of chronic lower-extremity ulcers. Wound Repair and Regeneration. 2008;16(6):749–756. doi:10.1111/j.1524-475X.2008.00426.x

8. Johnson KE, Wilgus TA. Vascular Endothelial Growth Factor and Angiogenesis in the Regulation of Cutaneous Wound Repair. Adv Wound Care (New Rochelle). 2014 Oct 1;3(10):647-661. doi: 10.1089/wound.2013.0517. PMID: 25302139; PMCID: PMC4183920.

9. Fridman R, Wielgomas J. A Prospective Study to Evaluate Efficacy and Safety of Autologous Platelet-Rich Fibrin Matrix for the Treatment of Chronic Diabetic Foot Ulcers. Clinical Research on Foot & Ankle. 2024;12(10):1-7. doi:https://doi.org/10.4172/2329-910X.1000590

Explore our Entire Product Line

Autologous Advanced Biologics

Cellular Bone Graft

Traditional Bone Grafts

Advanced Synthetics

Wound Care

About Royal

Royal is a pioneering leader in orthobiologic and wound care research and development. Royal’s commitment lies in delivering top-tier, innovative biologic solutions that enhance the healing process and improve patients' quality of life. Royal places patient well-being at the center of its mission, offering exceptional solutions to address a variety of complex needs.

At Royal, our mission is driven by patient-centered care, innovation and excellence, and integrity and compassion.
Royal provides a comprehensive array of products tailored to meet the varied needs of the orthobiologic and wound care industry.

As a rapidly expanding force in the industry, Royal is continuously developing and launching new products and solutions that set benchmarks for quality, effectiveness, and patient outcomes. Royal’s commitment to research and innovation keeps it at the forefront of the industry, helping to shape the future of healthcare and improving lives.